CAMBRIDGE, Mass.– KalVista Pharmaceuticals announced that it has granted stock options to five newly hired employees as part of an inducement to join the company. The options, totaling 50,000 shares of KalVista common stock, were approved by the compensation committee of the company’s board of directors on June 1, 2025.
The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to issue equity awards to new employees outside of shareholder-approved equity plans, provided the grants are a material component of employment terms.
Each option carries an exercise price equal to the closing price of KalVista’s stock on the grant date. The options will vest over a four-year period, with 25 percent vesting after the first year and the remaining shares vesting in equal monthly installments over the following three years, contingent on continued employment.
The options are issued under KalVista’s Inducement Equity Incentive Plan and are subject to standard terms outlined in the company’s stock option agreements. Each grant carries a 10-year term from the date of issuance.
